IGROV-1 HUMAN OVARIAN CANCER CELL LINE

General description

The IGROV-1 cell line is well-established as a model for drug-resistant ovarian carcinoma. IGROV-1 cells lack hormone receptors and exhibit low to moderate sensitivity to several common chemotherapeutic agents, while remaining sensitive to cisplatin (1). IGROV-1 cells harbor a paracentric inversion of chromosome 3 and a translocation between chromosomes 2 and 5 (1). The IGROV-1 cell line exhibits hypermutation and has an overall mutation profile similar to endometrioid carcinoma (2). IGROV-1 cells appear in culture as confluent monolayers and are highly tumorigenic in vivo, forming solid tumors within 15 days in nude mice (1). IGROV-1 cells are characterized by expression of vitronectin and αvα3 integrin, essential for the observed migratory behavior of these cells toward ECM proteins (3), and express the cancer-associated target MDM2 (4).

Source:
IGROV-1 cells were established from a stage III ovarian solid primary tumor of a 47-year-old female patient (1).

Research Category:
Cancer

Cell Line Origin

Human, Cancer Cells

Packaging

≥1X10⁶ cells/vial

Storage and Stability

Store in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

Other Notes

This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.